June 07, 2022

Astellas US LLC v. Hospira, Inc.

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. May 04, 2023

    Full Fed. Circ. Won't Rethink Decision On Heart Drug IP

    The Federal Circuit declined to rethink a decision rejecting Gilead Sciences' and Astellas' argument that they were wrongly barred from responding to amendments Hospira Inc. made to an abbreviated new drug application to allegedly skirt infringement of patents on cardiac stress agent Lexiscan.

6 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login